Vitura Health Flags Isolated Late Lodgement of Director Interest Notice

Cronos Australia Ltd. ( (AU:VIT) ) has issued an announcement.

Vitura Health Limited has disclosed a late lodgement of an Appendix 3Y notice relating to director Gerard Fogarty’s participation in the company’s dividend reinvestment plan, after an administrative oversight meant the securities issued on 30 September 2025 were not reported at the time. The company said the notice was filed promptly once the error was identified, described the incident as isolated, and reaffirmed that its existing reporting and notification processes remain adequate to ensure compliance with ASX director disclosure rules, signalling limited operational or governance impact for shareholders and other stakeholders.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

More about Cronos Australia Ltd.

Vitura Health Limited is an ASX-listed diversified digital health company focused on medicinal cannabis distribution, telehealth and emerging psychedelic therapies in Australia. Through subsidiaries including Burleigh Heads Cannabis and its Canview platform, Vitura operates a leading online ecosystem connecting prescribers, patients, pharmacies and suppliers, distributing more than 430 therapeutic product and device SKUs from around 60 brands. The company also owns the nationwide Doctors on Demand telehealth platform, medicinal cannabis telehealth clinics CDA Clinics and Cannadoc, and holds a 50% stake in Cortexa, a joint venture aiming to supply GMP-grade MDMA and psilocybin for research and therapeutic use, supported by state-of-the-art distribution centres in Melbourne and the Gold Coast licensed to handle a broad range of scheduled medicines.

Average Trading Volume: 269,978

Technical Sentiment Signal: Sell

Current Market Cap: A$40.43M

For a thorough assessment of VIT stock, go to TipRanks’ Stock Analysis page.